Acadia presents additional Phase 2 RADIANT data on remlifanserin for Alzheimer's psychosis
FROM THE WIRE · BUSINESSWIRE.COM
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) during an oral…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralNew Phase 2 clinical data can move a biotech stock, especially for a key program.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Acadia presented additional data from the Phase 2 RADIANT study at the CTAD 2026 conference in Boston.
- 02The study evaluates remlifanserin for hallucinations and delusions associated with Alzheimer's disease psychosis.
- 03New analyses provided further evidence of a consistent efficacy signal, building on previously announced topline results.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets